Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 09 Oct 2025, 21:49 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis evaluates UnitedHealth (UNH) using forward price-to-earnings ratios from Fiscal AI and a proprietary discounted cash flow model. It notes UNH's forward P/E of 22 and increase from lows of 14-13 earlier in the year. The DCF model suggests an intrinsic value of $449.17 per share, compared to a current market price of $358.77. The analyst believes the company undervalued, taking into account consistent free cash flow and customer base. The underperformance in 2025 is attributed to a company's misjudgment in estimates for how much it will cost to serve their customers, something correctable by adjusting the pricing policy. The last evaluation, on September 23rd, rated UNH as a buy, risk/reward remain attractive. The analyst acknowledges a business trading at a lower price will provide better opportunity, noting when it was trading at 275/250 or even 285. The analyst considers this a buy, rating to be confirmed.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
